A hearty congratulations to Dr. Andrew C. von Eschenbach for doing the right thing and moving Plan B from prescription to over-the-counter today when the FDA issued official notice of the Plan B Approval.
The delay of the Plan B switch signaled a serious departure by the FDA from evidence-based decision-making to being an agency that bends to the political needs of an Administration that wishes to appeal to a particular sector of voters.
The move to approve does demonstrate a huge quantity and quality of leadership on behalf of Dr. von Eschenbach. It eliminates the need to a recess appointment and opens the way for confirmation by the Senate. The combined effect goes a long way to restoring credibility to this fine agency after a long period of erosion.